Publication | Closed Access

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Patient-reported OutcomesGastrointestinal OncologyMedicineBiliary CancerPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchMolecular Oncology